MCB Alert: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Metropolitan Bank Holding Corp. (NYSE: MCB) Investors with Significant Losses to Contact Firm

Metropolitan Bank Holding reported Q2 2026 EPS of $1.54 versus roughly $2.28 consensus, as elevated credit-loss provisions, write-downs and charge-offs exposed worsening credit quality. New issues included a $26 million C&I non-performing loan, $14 million of unexpected charge-offs and a separate $10 million charge-off tied to a window-and-door manufacturer. MCB shares fell nearly 9% in one session, while Hagens Berman opened an investigation into whether the bank misrepresented reserve adequacy and the extent of legacy loan risks.

Analysis

The litigation announcement is not itself a new fundamental catalyst; plaintiff-firm investigations routinely follow sharp price declines and should not be treated as evidence of regulatory action or recoverable damages. The investable issue is whether the latest reserve build represents a one-quarter clean-up or the beginning of a migration in criticized C&I credits, which would force further provisioning, reduce tangible-book-value accretion, and compress MCB's valuation toward stressed regional-bank peers.

Near term, MCB is likely to trade on management credibility rather than reported earnings: investors will discount any assurance that problem credits are isolated until nonaccrual formation, criticized-loan balances, and reserve coverage stabilize for at least one to two reporting periods. A second reserve increase or new borrower-specific loss within the next 1-3 months would likely have disproportionate downside because it would imply underwriting or monitoring failures rather than an idiosyncratic resolution. Conversely, disclosed collateral recoveries, declining criticized assets, and a flat-to-lower provision in Q3 would undermine a bearish thesis quickly.

The less obvious spillover is a higher cost of capital for smaller banks with concentrated commercial portfolios, particularly where deposits or funding are less granular. That argues for an idiosyncratic MCB position rather than a broad regional-bank short: KRE exposure would add macro rate, deposit-beta, and CRE variables that are not necessary to capture the underwriting-credibility risk. Over 6-18 months, the key structural question is whether MCB must preserve capital through slower growth, tighter lending standards, or reduced capital returns; that outcome matters more than any eventual litigation settlement.

Key Decisions for Investors

• Do not buy MCB solely on the post-disclosure drawdown; wait for the next earnings release and detailed criticized/classified-loan, nonaccrual, and allowance-coverage disclosures. Treat a sequential increase in nonaccruals or provision expense as confirmation of a continuing credit-cycle short.
• For a 1-3 month tactical expression, consider short MCB on a relief rally versus long KRE in matched beta-adjusted notional. This isolates MCB-specific reserve and credibility risk; cover if Q3 provision expense normalizes and management demonstrates no incremental classified-loan migration.
• If borrow is expensive or liquidity is limited, use MCB put spreads expiring just after the next earnings date rather than naked puts. Size for a defined premium loss, since a credible portfolio-resolution update could drive a sharp short-covering rally after the existing selloff.
• Monitor funding costs, uninsured-deposit trends, tangible common equity and allowance-to-nonperforming-loan coverage. A material deterioration in any two of these metrics shifts the thesis from an earnings-reset trade to a balance-sheet-risk trade and warrants increasing conviction; stability across them is the key falsifier.